Lab
Pathadvantage, PA
Pathadvantage, PA was paid $4.75M by Medicaid between Jan 2018 and Dec 2024, across 83 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 13% of everything it billed.
33Billing provider infoPATHADVANTAGE, PA
DALLAS, TX 75205
DALLAS, TX 75205
33aNPI1053530758assigned 04/24/2007
33bProvider typeClinical Medical Laboratory
28Total paid$4.75M
24GClaims257,368
24DCodes billed83
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#27 of 436
Median peer was paid$17K
This provider vs. median275×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,828 | $42K | |
| 2019 | 1,350 | $26K | |
| 2020 | 19,703 | $245K | |
| 2021 | 57,424 | $837K | |
| 2022 | 59,244 | $1.18M | |
| 2023 | 66,331 | $1.40M | |
| 2024incomplete | 51,488 | $1.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 13% | 25,991 | 25,436 | $600K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 13% | 25,912 | 25,355 | $598K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 12% | 17,348 | 8,047 | $584K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 10% | 21,057 | 20,479 | $488K |
| 87481 | 10% | 21,644 | 10,551 | $486K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 7.0% | 20,838 | 20,651 | $331K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 4.5% | 10,390 | 10,294 | $212K |
| 87511 | 4.4% | 11,993 | 11,578 | $210K | |
| 87653 | 4.1% | 8,014 | 7,930 | $194K | |
| 88141 | 3.4% | 11,877 | 11,727 | $160K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.5% | 2,711 | 1,937 | $120K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.3% | 7,252 | 6,600 | $111K |
71 more codes
| 87563 | 2.1% | 4,212 | $100K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 1,805 | $67K |
| 88313 | 1.4% | 1,757 | $67K | |
| 85027 | <1% | 9,695 | $43K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,494 | $36K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,547 | $33K |
| 81007 | <1% | 1,583 | $32K | |
| 86762 | <1% | 2,907 | $26K | |
| 87340 | <1% | 3,622 | $23K | |
| 86850 | <1% | 3,308 | $20K | |
| 86780 | <1% | 2,269 | $19K | |
| 87625 | <1% | 710 | $15K | |
| 80053 | Comprehensive metabolic panel | <1% | 2,031 | $14K |
| 86592 | <1% | 4,712 | $13K | |
| 86803 | <1% | 1,515 | $13K | |
| 82105 | <1% | 1,167 | $13K | |
| 87529 | <1% | 625 | $12K | |
| 88342 | <1% | 276 | $11K | |
| 82950 | <1% | 3,254 | $10K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,514 | $9K |
| 87186 | <1% | 1,184 | $6K | |
| 87077 | <1% | 1,266 | $6K | |
| 88142 | <1% | 497 | $6K | |
| 86900 | <1% | 3,065 | $6K | |
| 86901 | <1% | 3,063 | $6K | |
| 82951 | <1% | 571 | $5K | |
| 84702 | <1% | 435 | $4K | |
| 80061 | Lipid panel | <1% | 613 | $4K |
| 86787 | <1% | 447 | $4K | |
| 87510 | <1% | 330 | $3K | |
| 87480 | <1% | 330 | $3K | |
| 87660 | <1% | 329 | $3K | |
| 84439 | <1% | 417 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 187 | $2K |
| 86696 | <1% | 172 | $2K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 88 | $2K |
| 83021 | <1% | 193 | $2K | |
| 88112 | <1% | 53 | $2K | |
| 82952 | <1% | 568 | $1K | |
| 86695 | <1% | 172 | $1K | |
| 80074 | <1% | 64 | $716.16 | |
| 0060U | <1% | 101 | $560.00 | |
| 87800 | <1% | 27 | $513.52 | |
| 81050 | <1% | 117 | $299.58 | |
| 88360 | <1% | 232 | $297.26 | |
| 82728 | <1% | 28 | $274.80 | |
| 84144 | <1% | 17 | $229.51 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 80 | $212.01 |
| 84146 | <1% | 15 | $196.99 | |
| 83001 | <1% | 15 | $142.05 | |
| 83002 | <1% | 13 | $141.60 | |
| 82570 | <1% | 25 | $92.23 | |
| 81003 | <1% | 100 | $87.32 | |
| 85660 | <1% | 20 | $78.24 | |
| 84156 | <1% | 27 | $74.23 | |
| 84550 | <1% | 15 | $53.20 | |
| 86593 | <1% | 13 | $33.67 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 29 | $0.00 |
| 81422 | 0% | 88 | $0.00 | |
| 81401 | 0% | 29 | $0.00 | |
| 81243 | 0% | 29 | $0.00 | |
| 81408 | 0% | 29 | $0.00 | |
| 81257 | 0% | 29 | $0.00 | |
| 81260 | 0% | 29 | $0.00 | |
| 81405 | 0% | 29 | $0.00 | |
| 81200 | 0% | 29 | $0.00 | |
| 81400 | 0% | 29 | $0.00 | |
| 81161 | 0% | 29 | $0.00 | |
| 81251 | 0% | 29 | $0.00 | |
| 81255 | 0% | 29 | $0.00 | |
| 81511 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGILLESPIE, ALEXANDRA (MEDICAL DIRECTOR)